Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gynomax XL in vaginal infections
NCT03839875Phase 4Completed
- Sponsor
- Exeltis
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Gynomax in trichomonal vaginitis, bacterial vaginosis (BV), candidal vulvovaginitis and 1 more, sponsored by Exeltis. Primary endpoint: Percentage of patients with complete response to treatment. Started Apr 2019; status: completed.
02
Drugs
Gynomax
03
Conditions
trichomonal vaginitisbacterial vaginosis (BV)candidal vulvovaginitismixed vaginitis
Beyond the preview
Go deeper on NCT03839875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03839875.